Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis [Corrigendum]
Thorlund K, Druyts E, Aviña-Zubieta JA, et al. Biologics: Targets and Therapy. 2012;6:417–427. On page 418, note that under Search strategy, Merck-Shire-Dome should have been listed as Merck, Sharp, and Dohme.On page 421, Figure 2, the relative risk for golimumab versus placebo...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c6de70e6bea54063ab316190353a8538 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:c6de70e6bea54063ab316190353a8538 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:c6de70e6bea54063ab316190353a85382021-12-02T01:31:57ZAnti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis [Corrigendum]1177-5475https://doaj.org/article/c6de70e6bea54063ab316190353a85382014-02-01T00:00:00Zhttp://www.dovepress.com/corrigendum-anti-tumor-necrosis-factor-tnf-drugs-for-the-treatmen-a15722https://doaj.org/toc/1177-5475 Thorlund K, Druyts E, Aviña-Zubieta JA, et al. Biologics: Targets and Therapy. 2012;6:417–427. On page 418, note that under Search strategy, Merck-Shire-Dome should have been listed as Merck, Sharp, and Dohme.On page 421, Figure 2, the relative risk for golimumab versus placebo for the PsARC response was incorrectly listed as 2.45, and should be 3.45. The mean difference for etanercept versus placebo for the PASI response was incorrectly listed as 2.13, and should be 3.13. The x-axis of the PASI forest plot was incorrectly labeled with mean difference values of 1, 2, 3 and 4. The correct values are 3, 6, 9 and 12.Read the original article Thorlund KDruyts EAviña-Zubieta JAMills EJDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2014, Iss default, Pp 57-58 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Thorlund K Druyts E Aviña-Zubieta JA Mills EJ Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis [Corrigendum] |
| description |
Thorlund K, Druyts E, Aviña-Zubieta JA, et al. Biologics: Targets and Therapy. 2012;6:417–427. On page 418, note that under Search strategy, Merck-Shire-Dome should have been listed as Merck, Sharp, and Dohme.On page 421, Figure 2, the relative risk for golimumab versus placebo for the PsARC response was incorrectly listed as 2.45, and should be 3.45. The mean difference for etanercept versus placebo for the PASI response was incorrectly listed as 2.13, and should be 3.13. The x-axis of the PASI forest plot was incorrectly labeled with mean difference values of 1, 2, 3 and 4. The correct values are 3, 6, 9 and 12.Read the original article |
| format |
article |
| author |
Thorlund K Druyts E Aviña-Zubieta JA Mills EJ |
| author_facet |
Thorlund K Druyts E Aviña-Zubieta JA Mills EJ |
| author_sort |
Thorlund K |
| title |
Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis [Corrigendum] |
| title_short |
Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis [Corrigendum] |
| title_full |
Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis [Corrigendum] |
| title_fullStr |
Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis [Corrigendum] |
| title_full_unstemmed |
Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis [Corrigendum] |
| title_sort |
anti-tumor necrosis factor (tnf) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis [corrigendum] |
| publisher |
Dove Medical Press |
| publishDate |
2014 |
| url |
https://doaj.org/article/c6de70e6bea54063ab316190353a8538 |
| work_keys_str_mv |
AT thorlundk antitumornecrosisfactortnfdrugsforthetreatmentofpsoriaticarthritisanindirectcomparisonmetaanalysiscorrigendum AT druytse antitumornecrosisfactortnfdrugsforthetreatmentofpsoriaticarthritisanindirectcomparisonmetaanalysiscorrigendum AT avintildeazubietaja antitumornecrosisfactortnfdrugsforthetreatmentofpsoriaticarthritisanindirectcomparisonmetaanalysiscorrigendum AT millsej antitumornecrosisfactortnfdrugsforthetreatmentofpsoriaticarthritisanindirectcomparisonmetaanalysiscorrigendum |
| _version_ |
1718403038826201088 |